Sarepta shares slammed on report gene therapy Duchenne MD patient was hospitalized, but the company says it is 'erroneous'
Sarepta has some explaining to do.
The biotech’s shares $SRPT nose dived 13% on Thursday after a report surfaced that one of the children in its gene therapy study was hospitalized with rhabdomyolysis in February, which hit the FDA’s adverse event roster. Its shares then plunged 13% before trading was halted.
Basic subscription required
Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.